Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023

Publisher Name :
Date: 28-Nov-2014
No. of pages: 57

GlobalData has released its new PharmaPoint Drug Evaluation report, "Avastin (Colorectal Cancer) Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Avastin was the first agent of a new class of drugs that targeted the angiogenesis pathway. The anti-angiogenic agent is a humanized monoclonal IgG1 that binds to vascular endothelial growth factor-A (VEGF-A), preventing the ligand from binding to the VEGF receptor. Inhibition of the VEGF pathway prevents endothelial cells from proliferating and forming the new bloods vessels that are required for the tumor to grow. The drug delivered as a monotherapy is not curative, and must be co-administered with a chemotherapy regimen.

Scope


  • Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

  • Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.

  • Sales forecast for Avastin for the top eight countries from 2013 to 2023.

  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.


Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return

  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer

  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

  • Make more informed business decisions from insightful and in-depth analysis of Avastin performance

  • Obtain sales forecast for Avastin from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Clinical Staging 14
3.3 Symptoms 16

4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Screening and Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 24

5 Competitive Assessment 31
5.1 Overview 31

6 Avastin (Bevacizumab) 33
6.1 Overview 33
6.2 Efficacy 35
6.3 Safety 35
6.4 SWOT Analysis 37
6.5 Forecast 37

7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 45
7.3 Methodology 48
7.4 Forecasting Methodology 48
7.4.1 Diagnosed Colorectal Cancer Patients 48
7.4.2 Percent Drug-Treated Patients 49
7.4.3 General Pricing Assumptions 49
7.4.4 Average Body Weight and Surface Area Across the 8MM 50
7.4.5 Individual Drug Assumptions 50
7.4.6 Generic Erosion 51
7.5 Primary Research - KOLs Interviewed for this Report 52
7.6 Primary Research - Prescriber Survey 53
7.7 About the Authors 54
7.7.1 Analyst 54
7.7.2 Global Head of Healthcare 55
7.8 About GlobalData 56
7.9 Disclaimer 56

List of Tables

Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile ? Avastin 34
Table 8: Avastin SWOT Analysis, 2014 37
Table 9: Global Sales Forecast ($m) for Avastin, 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 50
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53

  • Global Gene Therapy for Ovarian Cancer Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 06-Dec-2018        Price: US 3480 Onwards        Pages: 117
    Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has......
  • Global Acute Myeloid Leukemia Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 06-Dec-2018        Price: US 3480 Onwards        Pages: 132
    Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. Scope of the Report: This report studies ......
  • Global Small Molecule Targeted Cancer Therapy Market Size, Status and Forecast 2018-2025
    Published: 29-Nov-2018        Price: US 3900 Onwards        Pages: 94
    This report focuses on the global Small Molecule Targeted Cancer Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Small Molecule Targeted Cancer Therapy development in United States, Europe and China. In 2017, the global Small Molecule Targeted Cancer Therapy market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025. The key players c......
  • Global and Chinese Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry, 2018 Market Research Report
    Published: 28-Nov-2018        Price: US 3000 Onwards        Pages: 147
    The 'Global and Chinese Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry with a focus on the Chinese market. The report provides key statistics on the market status of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) manufacturers and is a valuable source of guidance and direction for com......
  • Global Non-small Cell Lung Cancer Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 27-Nov-2018        Price: US 3480 Onwards        Pages: 119
    Lung cancer is one of the most common malignant tumors in the world and has become the number one cause of death in malignant tumors in urban population in China. Non-small cell lung cancer accounts for about 80% of all lung cancers, and about 75% of patients are already in the advanced stage, and the 5-year survival rate is very low. Scope of the Report: This report studies the Non-small Cell Lung Cancer Therapeutics market status and outlook of Global and major regions, f......
  • Global Actinic Keratosis Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 121
    Actinic keratosis (AK) is a form of skin cancer and it is also known as solar keratosis. This indication tends to affect the sun-exposed parts of the skin such as face, bald scalp, lips, and the back of the hands among others. As a result of the exposure, the skin tends to become rough, uneven and display a warty look. Scope of the Report: The worldwide market for Actinic Keratosis Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach ......
  • Global Immuno-Oncology Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 15-Nov-2018        Price: US 3480 Onwards        Pages: 137
    Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers. Scope of the Report: The global Immuno-Oncology market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023. The Asia-Pacific will occupy for more market share in foll......
  • Global Acute Lymphoblastic Leukemia Therapeutics Market Insights, Forecast to 2025
    Published: 15-Nov-2018        Price: US 3900 Onwards        Pages: 125
    Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. In 2017, the global Acute Lymphoblastic Leukemia Therapeutics market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Acute Lymphoblastic Leukemia Therapeutics market based on company, product type, ap......
  • Lung Cancer Therapeutics: Global Markets
    Published: 14-Nov-2018        Price: US 5500 Onwards        Pages: 161
    Report Includes: - 34 data tables and 32 additional tables - An in-depth overview of the global market for lung cancer therapeutics within the industry - Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023 - Identification of key market dynamics, trends, opportunities and factors influencing the global lung cancer drug technology - Assessment of major regulatory pathway......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs